DCTD Synthetic Chemistry

DCTD合成化学

• 批准号: 7789121
• 负责人: LARRY ARTHUR
• 金额: $ 130万
• 依托单位: SCIENCE APPLICATIONS INTERNATIONAL CORP
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-09-26 至 2018-09-25
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7789121
• 关键词: DCTD; Synthetic; Chemistry

The Laboratory of Synthetic Chemistry (LSC) has been established with a primary preclinical objective to provide chemistry support to the cancer drug discovery and development efforts of the Developmental Therapeutics Program and the projects approved by the Joint Development Committee of DCTD-CCR (JDC). Towards this end LSC will focus its activities on lead optimization, an essential and integral part of new drug discovery and development. Novel synthetic methodologies will be developed to create new analogs based on the effective lead compounds to improve pharmaceutical profiles by addressing the following drug properties: activity, tumor selectivity, solubility, bioavailability, stability and ADME/PK in an iterative fashion. The laboratory is engaged in developing new relevant synthesis methodologies for applications by the wider extramural community, especially those funded by DCTD. Most recently, DCTD in conjunction with the Center for Cancer Research and the Office of the Director, NCI established a new program called the Chemical Biology Consortium (CBC) to facilitate the discovery and development of new agents to treat cancer. The CBC is expected to be an integrated research consortium at the cutting edge of chemical biology and molecular oncology that will work with various programs within NCI and outside scientific community, establish an iterative cancer drug discovery group on the scale of a small biotechnology concern, and advance new cancer therapy into the clinic. The goal of the CBC is to focus on unmet therapeutic needs in oncology that are not currently addressed by the private sector, including the pharmaceutical industry. To address this challenge and to re-establish NCI as a major player in the national cancer therapeutic arena, successful interaction of CBC Screening and Chemistry centers and other scientific groups is necessary. To achieve this goal, the LSC has become the CBC Chemistry support center that will interact with various DCTD centers and programs within NCI and outside contractor laboratories to facilitate the identification of new drug discoveries through medicinal chemistry with the ultimate goal of developing new clinical candidates.

合成化学实验室（LSC）的主要临床前目标是为开发治疗项目的癌症药物发现和开发工作以及DCTD-CCR联合开发委员会（JDC）批准的项目提供化学支持。为此，LSC将把活动重点放在先导化合物优化上，这是新药发现和开发的重要组成部分。将开发新的合成方法以基于有效的先导化合物来创建新的类似物，以通过以迭代方式解决以下药物性质来改善药物特性：活性、肿瘤选择性、溶解度、生物利用度、稳定性和ADME/PK。该实验室正在开发新的相关综合方法，供更广泛的校外社区，特别是由DCTD资助的社区应用。 最近，DCTD与癌症研究中心和主任办公室合作，NCI建立了一个名为化学生物学联盟（CBC）的新项目，以促进发现和开发治疗癌症的新药物。CBC预计将成为化学生物学和分子肿瘤学前沿的综合研究联盟，将与NCI内外科学界的各种项目合作，建立一个小型生物技术关注规模的迭代癌症药物发现小组，并将新的癌症疗法推进临床。CBC的目标是关注目前私营部门（包括制药行业）尚未满足的肿瘤治疗需求。为了应对这一挑战，并重新建立NCI作为国家癌症治疗竞技场的主要参与者，CBC筛查和化学中心以及其他科学团体的成功互动是必要的。为了实现这一目标，LSC已成为CBC化学支持中心，将与NCI和外部承包商实验室内的各种DCTD中心和项目进行互动，以促进通过药物化学识别新药发现，最终目标是开发新的临床候选药物。